...
【24h】

The renal natriuretic peptide urodilatin is present in human kidney.

机译:肾利钠肽尿苷素存在于人肾中。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: The natriuretic peptide urodilatin was first isolated from human urine and may be one of the important mediators of natriuresis, while the atrial natriuretic peptide alpha-ANP, the circulating member of the family, rather seems to play a role in cardiovascular regulation. Although the renal expression of the common propeptide for urodilatin and alpha-ANP has been detected in rat and pig, it is not yet shown that urodilatin is synthesized in human kidney. METHODS: Immunohistochemically we localized urodilatin with an urodilatin-antibody, which does not cross-react with alpha-ANP, the ANP propeptide, brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). Radiolabelled urodilatin binding was examined autoradiographically. RESULTS: We could demonstrate that urodilatin is present in human distal tubular cells, in which we could also localize propeptide immunoreactivity. The glomeruli, the cells of the proximal tubule, and the collecting duct did not show any urodilatin immunoreactivity. In human kidney homogenate the urodilatin content was 4600 + 520 fmol/g protein (n = 6). The renal concentration of BNP and CNP, mainly localized in the distal tubule, was much lower at 40 + 8 and 400+/-50 fmol/g protein (n=6) respectively. Furthermore the autoradiographic examinations showed that radiolabelled urodilatin binds to natriuretic peptide receptors in the glomeruli, blood vessels, and collecting ducts. CONCLUSIONS: Our data suggest that urodilatin may be the predominant representative of natriuretic peptides in human kidneys. Urodilatin being synthesized in the distal tubular region may be transported as a paracrine factor to the collecting duct, where it exerts its suppressing effect on the sodium reabsorption by stimulating the guanylyl cyclase A.
机译:背景:利尿钠尿嘧啶肽最初是从人尿中分离出来的,可能是利尿钠的重要介质之一,而心钠素家庭中的循环成员,似乎在心血管调节中发挥了作用。尽管已经在大鼠和猪中检测到了尿嘧啶核苷和α-ANP的通用原肽在肾脏中的表达,但尚未显示尿嘧啶核苷在人肾脏中合成。方法:免疫组织化学中,我们将urodilatin定位于urodilatin抗体,该抗体不会与α-ANP,ANP前肽,脑利钠肽(BNP)和C型利钠肽(CNP)发生交叉反应。用放射自显影检查放射性标记的urodilatin结合。结果:我们可以证明人远端肾小管细胞中存在urodilatin,我们还可以在其中定位前肽免疫反应性。肾小球,近端小管细胞和收集管未显示任何urodilatin免疫反应性。在人肾脏匀浆中,urodilatin含量为4600 + 520 fmol / g蛋白(n = 6)。 BNP和CNP的肾脏浓度主要位于远端小管,分别较低,分别为40 + 8和400 +/- 50 fmol / g蛋白(n = 6)。此外,放射自显影检查显示放射性标记的urodilatin与肾小球,血管和收集管中的利钠肽受体结合。结论:我们的数据表明,urodilatin可能是人肾脏中利钠肽的主要代表。在远端管状区域合成的乌罗地他汀可以作为旁分泌因子运输到收集管,在那里它通过刺激鸟苷酸环化酶A对钠重吸收发挥抑制作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号